Global Pelvic Inflammatory Disease (PID) Market, By Drug Class (Macrolides, Tetracycline, Beta-lactam, Nitroimidazoles, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Pelvic Inflammatory Disease (PID) Market Analysis and Size
The pelvic inflammatory disease (PID) market is expected to witness significant growth during the forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The growth of pelvic inflammatory disease (PID) market enhanced by the growing cases of sexually transmitted diseases and rise in research and development activities conducted by many pharmaceutical companies. In addition, advances in treatment options and well-established healthcare facilities are some of the impacting factors for the demand for PID treatment drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global pelvic inflammatory disease (PID) market in the forecast period 2022-2029. The expected CAGR of pelvic inflammatory disease (PID) market is tend to be around 5.60% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Pelvic inflammatory disease (PID) is defined as the infections of the female genital tract. The pelvis region includes the lower abdomen which comprised of fallopian tubes, ovaries, cervix, and the uterus. It is occurring when bacteria causing sexually transmitted diseases is spread from the vagina to other parts of the female reproductive system. The characteristics sign and symptoms includes pelvic pain and fever.
Pelvic Inflammatory Disease (PID) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Macrolides, Tetracycline, Beta-lactam, Nitroimidazoles, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Mayne Pharma Group Limited (Australia), Pfizer Inc (U.S.), AstraZeneca (U.K.), Johnson and Johnson services Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Janssen Pharmaceuticals, Inc. (Belgium), Sanofi (France), Merck & Co., Inc (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Bristol Myers Squibb Company (U.S.)
|
|
Market Opportunities
|
|
Global Pelvic Inflammatory Disease (PID) Market Dynamics
Drivers
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the global hematuria treatment market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Rise in Lifestyle Changes and Associated Disorders
Changes in lifestyle can result in causing disorders such as menopausal disorders, polycystic ovary syndrome, uterine fibroids, endometriosis, trichomoniasis, HIV/AIDS, etc which increases the revenue in the region. For instance, according to the Centers for Disease Control and Prevention CDC, PCOS affected around 6% to 12% women of reproductive age and 1 in 8 women with a history of PID experience difficulties getting pregnant in the United States. Thus, it is creating opportunity for the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of PID therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global pelvic inflammatory disease (PID) market over a forecast period.
- High Cost
The huge expenditure associated with PID treatment medications surely hamper the market growth.
This pelvic inflammatory disease (PID) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pelvic inflammatory disease (PID) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Pelvic Inflammatory Disease (PID) Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. The transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will significantly impact the pelvic inflammatory disease (PID) market.
Global Pelvic Inflammatory Disease (PID) Market Scope
The pelvic inflammatory disease (PID) market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Macrolides
- Tetracycline
- Beta-lactam
- Nitroimidazoles
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Pelvic Inflammatory Disease (PID) Market Regional Analysis/Insights
The pelvic inflammatory disease (PID) market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the pelvic inflammatory disease (PID) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global pelvic inflammatory disease (PID) market throughout the forecasted period due to the global leaders in research and development activities, established framework of approval process and increase in number of FDA approval drugs.
Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Antidotes Market Share Analysis
The pelvic inflammatory disease (PID) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pelvic inflammatory disease (PID) market
Key players operating in the pelvic inflammatory disease (PID) market include:
- Mayne Pharma Group Limited (Australia)
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Johnson and Johnson services Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Janssen Pharmaceuticals, Inc. (Belgium)
- Sanofi (France)
- Merck & Co., Inc (U.S.)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Bristol Myers Squibb Company (U.S.)
SKU-